

TOS summit winter session暨會員大會

➤ 2020/10/17 (Sat.) 張榮發會議中心八樓

	801 會議室	803 會議室
08:30~09:00	報到	
09:00~09:20	徐千田癌傑獎頒獎	
09:20~10:00	徐千田癌傑獎演講(林家齊教授)	
10:00~10:40	徐千田癌傑獎演講(何元順教授)	10:00~10:40 第二十屆第二次會員大會 (限會員參加)
10:40~11:00	Break	
11:00~11:30	speaker:吳教恩醫師	
11:30~12:00	<i>Advances of Antibody Drug Conjugate in Solid Tumor</i> speaker:陳明晃醫師	<i>Evolving Landscape of Systemic Therapy for HCC: How does the future look?</i> speaker:邵幼雲醫師
12:00~12:30	<i>GI session</i> speaker:徐志宏教授	
12:30~13:10	Lunch	
13:10~13:40	<i>Key considerations for emerging treatments in HCC: biomarkers and safety update</i> speaker:呂理駿醫師	
13:40~14:10	<i>Current Status and Future Perspective of Immunotherapy in Upper</i> speaker:梁逸歆醫師	<i>Radium-223:Optimizing Treatment in mCRPC Patients with Radium-223</i> speaker:蘇柏榮醫師
14:10~14:40	<i>GI session</i> speaker:陳三奇醫師	<i>The role of PARPi in prostate cancer – from precision medicine to survival impact</i> speaker:蘇祐立醫師
14:40~15:00	Break	
15:00~15:30	<i>NTRK fusion - A revolutionary new approach to cancer treatment</i> speaker:謝佳訓醫師	<i>Raising the caliber of nmCRPC Care: Introducing Quality of Life into the Equation</i> speaker:魏子鈞醫師
15:30~16:00	<i>New era of immunotherapy in mRCC: Nivolumab as a backbone in combination with anti-CTLA4 or TKI in front-line setting</i> speaker:蔡育傑醫師	
16:00~16:30	<i>Reshaping treatment paradigms for GU cancer patients: perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in mUC</i> speaker:沈盈君醫師	

► 2020/10/18 (Sun.) 張榮發會議中心八樓

	801 會議室	803 會議室	
08:30~09:00	報到		
09:00~09:50	董大成癌傑獎頒獎暨演講(潘敏雄教授)		
09:50~10:00	癌症醫學終身成就獎頒獎(陳博明教授)		
10:00~10:30	<i>The Evolving Therapeutic Landscape for HR+, HER2- Early Breast Cancer</i> speaker: Prof. Rugo		
10:30~10:50	Break		
10:50~11:20	LC session	10:50~11:00	年輕研究者癌症研究傑出論文獎頒獎 (李杰醫師、許家齊博士)
11:20~11:50	<i>Frontline Immunotherapy Treatment Options in mNSCLC, what we can know from 5-yr KEYNOTE-024 data?</i> speaker: 楊志新院長	11:00~11:50	年輕研究者癌症研究傑出獎頒獎暨演講(李健逢醫師)
11:50~12:20	LC session		
12:20~13:00	Lunch		
13:00~13:30	<i>New strategy for front-line treatment: multiple IO Combo regimens in advanced NSCLC (CM 227, CM-9LA, ONO-052 trial)</i> speaker: 李岡遠醫師	<i>Updated ESMO Guidelines: Bone health in cancer – focus on Breast cancer</i> speaker: 沈雯琪醫師	
13:30~14:00	BC session	Targeting Actionable KRAS Mutation in NSCLC speaker: 蔡俊明教授	
14:00~14:30	BC session speaker: 戴明榮醫師	LC session speaker: 楊展庚醫師	
14:30~14:40	Break		
14:40~15:10	<i>The role of PIK3CA mutation and PI3K inhibitor in HR+ HER2- advanced breast cancer.</i> speaker: 陳偉武醫師	LC session speaker: 廖斌志醫師	
15:10~15:40	<i>Footprints in DDR driven cancers- now and future</i> speaker: 劉建廷醫師		

主辦單位：中華民國癌症醫學會

報名方式：請至癌症醫學會網站，線上報名。

<http://www.taiwanoncologysociety.org.tw/ehc-tos/s/w/edu/scheduleInfo1/schedule1/5195>